Intellipharmaceutics International Inc. (IPCI)

[wimuskyfisherman]

What will make or break IPCI is Rexista HAP studies. If they are very good, a strong partner will follow along with reasonable chance for approval. If not spectacular, no partner and no chance of approval. It all comes down to Rexista. ANDAs at this point are pretty much a failed business plan. Regabatin is nothing without a partner. All the IP IPCI claims to have is nothing without a way to monetize it. The only thing that can save the company is Rexista and a strong partner handling the FDA side.